Ocugen

MALVERN, Pa. — September 25, 2026 Ocugen Inc. announced that its investigational modifier gene therapy OCU400 has received provisional...

MALVERN, Pa., Sept. 1, 2026 Ocugen, Inc. has announced that the first patient has been dosed in the global...

MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...

MALVERN, Pa., July 13, 2026 Ocugen announced the signing of a binding term sheet with Roots Pharmaceutical and its...

MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...

MALVERN, Pennsylvania, USA | March 24, 2026 In a major breakthrough for retinal disease treatment, Ocugen, Inc. has announced...

MALVERN, Pa., January 12, 2026 — Ocugen, Inc. announced the peer-reviewed publication of positive Phase 1 GARDian1 clinical trial...